The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310058, China
Location status: Recruiting
NCT Number: NCT06636201
The aim of this study is to explore the role of cerebrospinal fluid (CSF) biomarkers in aging and neurodegenerative diseases.
Interested in participating?
Request Info0 year–90 year
All sexes
Observational
Hangzhou, Zhejiang, 310058, China
Location status: Recruiting
This study aims to investigate the role of cerebrospinal fluid (CSF) biomarkers in aging and neurodegenerative diseases, with a focus on the following objectives:
Analysis of Age-Related Changes in CSF Biomarkers: The study will analyze CSF samples from different age groups to identify biomarkers that undergo significant changes during the aging process. This includes the investigation of amyloid-beta (Aβ42), Tau proteins (including the phosphorylated form p-tau181), and other proteins related to neuroinflammation and blood-brain barrier function.
Development of a Predictive Model for Early Diagnosis: By categorizing and quantifying CSF proteins across various age groups, the study aims to establish a predictive model for the early diagnosis of neurodegenerative diseases, such as Alzheimer's disease. The ability to detect these diseases before clinical symptoms emerge could enable early intervention and treatment, offering a crucial window for therapeutic strategies.
Investigation of Dynamic Changes in CSF Biomarkers Across Disease Stages: The study will examine the dynamic changes in CSF biomarkers at different stages of neurodegenerative diseases, including early, middle, and late stages. Understanding the role of these biomarkers in disease progression will provide insights into the pathological processes and potential therapeutic windows.
Creation of a Comprehensive CSF Biomarker Database: A database will be established, encompassing CSF biomarkers from various age groups, disease states, and treatment responses. This resource will be invaluable for future research, facilitating the scientific community's understanding of neurodegenerative diseases and the development of new therapeutic approaches.
Through the achievement of these objectives, this study aims to advance the application of CSF biomarkers in neuroscience research and clinical practice, ultimately improving the diagnosis, management, and treatment of aging-related and neurodegenerative conditions.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Time frame: December 2024
CSF samples from different ages were analyzed to identify biomarkers that change significantly during aging, such as amyloid beta (Aβ42), Tau protein (including the phosphorylated form p-tau181), and other proteins associated with neuroinflammation and blood-brain barrier function
Contact information is provided by the study sponsor or research team.
Junming Zhu, MD. phD
CONTACT
Wei Gao
CONTACT
Second Affiliated Hospital, School of Medicine, Zhejiang University
Other
Deputy Director of Department of Neurosurgery, the Second Affiliated Hospital of Zhejiang University School of Medicine;Professor;
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07646782
Activities of Daily Living, Aging
Boulder, Colorado, United States
View Trial DetailsNCT06572332
Aging, Brain
Hong Kong
View Trial DetailsNCT04793555
Activities of Daily Living, Aging
Bern, Ber, Switzerland
View Trial DetailsNCT04315038
Aging, Metabolites
Taoyuan, Taiwan
View Trial Details